Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins

被引:107
|
作者
Short, SM
Derrien, A
Narsimhan, RP
Lawler, J
Ingber, DE
Zetter, BR [1 ]
机构
[1] Harvard Univ, Sch Med, Vasc Biol Program, Childrens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[4] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA
[5] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
来源
JOURNAL OF CELL BIOLOGY | 2005年 / 168卷 / 04期
关键词
D O I
10.1083/jcb.200407060
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The anti-angiogenic effect of thrombospondin-1 has been shown to be mediated through binding of the type-1 repeat (TSR) domain to the CD36 transmembrane receptor. We now report that the TSR domain can inhibit VEGF-induced migration in human umbilical vein endothelial cells (HUVEC), cells that lack CD36. Moreover, we identified beta(1) integrins as a critical receptor in TSR-mediated inhibition of migration in HUVEC. Using pharmacological inhibitors of downstream VEGF receptor effectors, we found that phosphoinositide 3-kinase (PI3k) was essential for TSR-mediated inhibition of HUVEC migration, but that neither PLCgamma nor Akt was necessary for this response. Furthermore, beta1 integrins were critical for TSR-mediated inhibition of microvascular endothelial cells, cells that express CD36. Together, our results indicate that P, integrins mediate the anti-migratory effects of TSR through a PI3k-dependent mechanism.
引用
收藏
页码:643 / 653
页数:11
相关论文
共 50 条
  • [21] Mechanism of inhibition of tumoral angiogenesis by thrombospondin-1
    Cuenca, BJ
    NEFROLOGIA, 2003, 23 : 49 - 53
  • [22] Endothelial Cell Behavior Is Determined by Receptor Clustering Induced by Thrombospondin-1
    Morandi, Veronica
    Petrik, Jim
    Lawler, Jack
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [23] Thrombospondin-1 Triggers Cell Migration and Development of Advanced Prostate Tumors
    Firlej, Virginie
    Mathieu, Jacques R. R.
    Gilbert, Cristele
    Lemonnier, Loic
    Nakhle, Jessica
    Gallou-Kabani, Catherine
    Guarmit, Basma
    Morin, Aurelie
    Prevarskaya, Natalia
    Delongchamps, Nicolas Barry
    Cabon, Florence
    CANCER RESEARCH, 2011, 71 (24) : 7649 - 7658
  • [24] Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1
    Yu, HN
    Tyrrell, D
    Cashel, J
    Guo, NH
    Vogel, T
    Sipes, JM
    Lam, L
    Fillit, HM
    Hartman, J
    Mendelovitz, S
    Panel, A
    Roberts, DD
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 374 (01) : 13 - 23
  • [25] Expression, purification and structural characterization of functionally replete thrombospondin-1 type 1 repeats in a bacterial expression system
    Klenotic, Philip A.
    Page, Richard C.
    Misra, Saurav
    Silverstein, Roy L.
    PROTEIN EXPRESSION AND PURIFICATION, 2011, 80 (02) : 253 - 259
  • [26] Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration
    Chan, Lai Yue
    Craik, David J.
    Daly, Norelle L.
    BIOSCIENCE REPORTS, 2015, 35
  • [27] Thrombospondin-1 in pulmonary artery smooth muscle cell growth inhibition
    Hasak, Stephen Lawler
    Ochoa, Cristhiaan D.
    Quinn, Deborah A.
    Hales, Charles
    FASEB JOURNAL, 2007, 21 (06): : A1435 - A1435
  • [28] Nitric-oxide mediated inhibition of platelet function is reversed by thrombospondin-1
    Roberts, W.
    Riba, R.
    Naseem, K. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 938 - 939
  • [29] Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle
    Yamauchi, Mai
    Imajoh-Ohmi, Shinobu
    Shibuya, Masabumi
    CANCER SCIENCE, 2007, 98 (09): : 1491 - 1497
  • [30] Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model
    Zhang, XF
    Galardi, E
    Duquette, M
    Lawler, J
    Parangi, S
    CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5622 - 5630